AD/HD Under the Microscope

Attention Deficit/Hyperactivity Disorder (AD/HD) sits at an uncomfortable crossroads of neuroscience, education, culture and commerce. The construct is simultaneously one of the most robustly replicated findings in child psychiatry — heritable, impairing, and responsive to stimulant medication — and one of the most contested diagnoses in contemporary medicine, with prevalence rates, diagnostic thresholds and treatment practices varying so widely across time and place that critics question whether the category describes a discrete condition at all. A defensible clinical and academic position, as this article will argue, is that AD/HD is neither a simple neurobiological disease nor a social fiction. It is a genuinely impairing behavioural syndrome at its severe end, but its diagnostic boundaries are porous, its phenotype heterogeneous, and its current expansion — particularly into adult presentations — runs ahead of the evidence base. This article is an attempt to hold both truths at once, giving weight to the evidence for validity while taking critique seriously rather than dismissing it as ideological noise.

1. What we are talking about: diagnostic criteria and their history

The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR; American Psychiatric Association [APA], 2022) defines AD/HD as a neurodevelopmental disorder characterised by a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development. The manual lists two symptom domains of nine items each. The inattention domain includes careless mistakes, difficulty sustaining attention, apparent non-listening, failure to follow through, disorganisation, avoidance of sustained mental effort, losing things, easy distractibility, and forgetfulness. The hyperactivity-impulsivity domain includes fidgeting, leaving one’s seat, inappropriate running or climbing, inability to engage in leisure quietly, being “on the go”, talking excessively, blurting answers, difficulty waiting turns, and interrupting. For diagnosis in children up to age 16, at least six symptoms must be present in one or both domains; for adolescents from age 17 and adults, the threshold was reduced to five. Several symptoms must have been present before age 12 (raised from age 7 in DSM-IV), appear in two or more settings, interfere with functioning, and not be better explained by another disorder (APA, 2022). Three “presentations” are specified — predominantly inattentive, predominantly hyperactive-impulsive, and combined — replacing the DSM-IV “subtypes” to reflect longitudinal instability of the categories. Critically for current practice, DSM-5 also removed the prohibition on diagnosing AD/HD alongside autism spectrum disorder, opening the diagnostic door to a large co-occurring population.

The World Health Organisation’s International Classification of Diseases, 11th Revision (ICD-11; WHO, 2022) aligned closely with DSM-5 under code 6A05, abandoning the narrower ICD-10 construct of “hyperkinetic disorder” (F90), which had required the simultaneous presence of severe inattention, hyperactivity and impulsivity in multiple settings and had historically produced European prevalence estimates roughly one-fifth of those reported in the United States. The shift in ICD-11 — recognising inattention-only presentations and permitting adult diagnosis — represents a substantive widening of the disorder internationally.

The construct itself is not new, but its boundaries have moved repeatedly. Credit for the first modern clinical description usually goes to the British paediatrician George Still (1902), whose Royal College of Physicians lectures described children with “an abnormal defect of moral control”. After the 1917–1928 encephalitis lethargica epidemic, physicians observed behavioural sequelae — restlessness, impulsivity, inattention — that fed into the mid-century concept of “minimal brain damage” and later “minimal brain dysfunction” (MBD), inferring organic pathology from behaviour in the absence of demonstrable lesions. Bradley’s (1937) serendipitous discovery that benzedrine calmed disruptive children established the pharmacological template that persists today. The DSM-II (1968) introduced “Hyperkinetic Reaction of Childhood”. The intellectual turn came with DSM-III (1980), when Virginia Douglas’s cognitive-psychology research on sustained attention shifted the emphasis from motor activity to attentional deficit, yielding “Attention Deficit Disorder” (with or without hyperactivity). DSM-III-R (1987) reunified the construct as a single category; DSM-IV (1994) introduced subtypes; DSM-5 (2013) and DSM-5-TR (2022) loosened thresholds for adults and adolescents. Every revision in the past four decades has expanded rather than narrowed the diagnostic territory, a pattern that critics regard as evidence of concept creep rather than scientific refinement.

Epidemiology — numbers that do not settle

Prevalence estimates vary by an order of magnitude depending on method. Polanczyk, de Lima, Horta, Biederman and Rohde’s (2007) foundational meta-analysis of 102 studies pooled worldwide childhood prevalence at 5.29% (95% CI 5.01–5.56). The updated meta-regression by Polanczyk, Willcutt, Salum, Kieling and Rohde (2014) gave 3.4% in children and adolescents and concluded that previously reported geographic variation was largely methodological rather than real. Thomas, Sanders, Doust, Beller and Glasziou (2015) produced a higher pooled estimate of 7.2% in children. Willcutt’s (2012) DSM-IV–specific meta-analysis found similar rates (5.9–7.1%) regardless of informant. The World Federation of ADHD’s International Consensus Statement (Faraone et al., 2021) settled on 5.9% of youth and 2.5% of adults as working figures — the adult estimate drawn largely from Simon, Czobor, Bálint, Mészáros and Bitter (2009) and Fayyad et al. (2017). Adult symptom-level prevalence has risen in subsequent meta-analyses (Song et al., 2021, reported persistent adult AD/HD at 2.58% and symptomatic adult AD/HD at 6.76%).

These research-criteria figures diverge sharply from administrative diagnosis rates. United States Centers for Disease Control and Prevention data from the National Survey of Children’s Health show that approximately 11.4% of American children aged 3–17 had ever been diagnosed with AD/HD by 2022, a figure roughly double the international research prevalence and triple the rates observed in countries such as France or Japan. Adult prescribing in the US, UK and Australia surged between 2020 and 2024 in a wave that some commentators have linked to pandemic disruption, telehealth expansion and social-media–driven self-identification (Chung et al., 2023). These administrative numbers cannot be reconciled with a stable biological prevalence; something is moving, and it is not the underlying neurobiology.

2. Presentation in males and females

The textbook childhood AD/HD patient has long been the disruptive, seat-leaving, answer-blurting boy, and clinical samples reflect this image. Ramtekkar, Reiersen, Todorov and Todd (2010), analysing the National Comorbidity Survey Replication and a large US sibling sample, found childhood clinical male:female ratios of approximately 3:1 to 4:1 but community ratios closer to 2:1 for combined presentation and near parity for inattentive presentation. In adult community samples the ratio approaches 1:1 (Willcutt, 2012), yet clinical referrals remain male-weighted. The mismatch between community and clinic ratios is itself a clue that something other than disorder prevalence — most plausibly referral bias — shapes who receives a diagnosis.

The “female phenotype” of AD/HD, developed over three decades by Nadeau, Quinn, Hinshaw and colleagues, emphasises a predominantly inattentive, cognitively disorganised picture with internalising comorbidity rather than conduct problems. The Berkeley Girls with ADHD Longitudinal Study (BGALS; Hinshaw et al., 2012) demonstrated that girls diagnosed with combined-type AD/HD in childhood had markedly elevated rates of self-harm and suicide attempts by young adulthood compared with comparison girls, despite their lower external visibility in childhood. Young et al.’s (2020) consensus on the recognition and treatment of AD/HD in girls and women argued that masking, camouflaging and compensatory strategies delay diagnosis until adolescence or adulthood, often after a crisis in academic transition, workplace demand or motherhood.

Hormonal modulation adds another layer. Oestrogen potentiates dopaminergic transmission in the prefrontal cortex, and symptoms appear to fluctuate across the menstrual cycle, with worsening in the late luteal and perimenstrual phases (Roberts, Eisenlohr-Moul & Martel, 2018). Clinical reports and emerging cohort data describe a perimenopausal exacerbation of executive and attentional difficulties (de Jong, Wynchank, Michielsen, Beekman & Kooij, 2023), which some clinicians now treat as a late-presenting AD/HD unmasked by oestrogen withdrawal and others regard as a non-specific menopausal cognitive change.

The critical question is whether sex differences in AD/HD are biological, artefactual, or both. The male-weighted original field-trial samples of DSM-III and DSM-IV skewed the criterion set toward externalising behaviour most readily observed in boys. A girl who is quietly lost inside her own head will not reliably elicit the “climbs or runs inappropriately” or “often leaves seat” criteria. The probable truth is mixed: there is genuine biological skew — sex differences in dopaminergic systems, in brain maturation timing, and in the interaction of AD/HD genetic liability with male vulnerability to externalising expression — but the diagnostic criteria are male-normed in ways that systematically under-identify the female phenotype. The current surge in adult female diagnoses represents, in part, a legitimate correction of historical under-recognition; it also represents, in part, the rebranding of non-specific cognitive and emotional distress as a neurodevelopmental disorder.

3. Childhood versus adulthood: the same disorder?

Childhood AD/HD is, in the main, an observable behavioural phenomenon. Teachers and parents are the primary informants, the child is rarely the reporter of their own symptoms, and the behaviours in question — classroom disruption, homework failure, peer conflict, emotional volatility — are in plain view. Parent–teacher agreement on AD/HD symptoms is nonetheless modest (typical rater correlations of r ≈ 0.3–0.4; Achenbach, McConaughy & Howell, 1987), which is itself a reminder that the phenotype is context-dependent.

Adult AD/HD looks different. Overt motor hyperactivity attenuates with age, replaced by subjective restlessness, chronic disorganisation, difficulty initiating and completing tasks, poor time management (Barkley’s “time blindness”), and — increasingly recognised as a core rather than an associated feature — emotional dysregulation (Shaw, Stringaris, Nigg & Leibenluft, 2014; Faraone, Rostain, Blader, Busch, Childress, Connor & Newcorn, 2019). Rejection-sensitive dysphoria has entered the clinical lexicon via Dodson and popular media but remains an under-researched construct with a thin peer-reviewed evidence base. The central diagnostic instrument for adults — the self-report rating scale — is however a weak measuring stick. Sibley, Pelham, Molina, Gnagy, Waxmonsky, Waschbusch et al. (2012) and Sibley et al. (2018) showed that adult self-reports of AD/HD symptoms correlate only modestly with informant reports, with objective performance data, and with cross-situational observation. Barkley and Fischer (2019) went further, arguing that unaided adult self-report is insufficient for valid diagnosis.

The adult-onset controversy

The question of whether adult AD/HD is always a continuation of a childhood disorder has become one of the most consequential debates in the field. Three prospective birth cohorts published almost simultaneously delivered a startling finding. Moffitt, Houts, Asherson, Belsky, Corcoran, Hammerle et al. (2015), analysing the Dunedin cohort of 1,037 New Zealanders followed from age 3 to 38, reported that childhood AD/HD had a 6% prevalence (predominantly male) and adult AD/HD had a 3% prevalence (gender balanced) — but that 90% of the adult AD/HD cases lacked any history of childhood AD/HD, and, strikingly, the adult group showed neither neuropsychological deficits nor elevated polygenic risk for childhood AD/HD. Agnew-Blais, Polanczyk, Danese, Wertz, Moffitt and Arseneault (2016), using the Environmental Risk (E-Risk) twin cohort of 2,232 twins in England and Wales, found that 67.5% of young adults meeting AD/HD criteria had not done so in childhood. Caye, Rocha, Anselmi, Murray, Menezes, Barros et al. (2016), in the 1993 Pelotas Birth Cohort from Brazil, replicated the pattern. Across the three cohorts, between 67.5% and 90% of adult-onset cases had no evidence of childhood AD/HD.

The findings provoked vigorous rebuttal. Faraone and Biederman (2016), Sibley et al. (2018) and others argued that apparent “adult-onset” cases often dissolve when one controls for substance use, depression, anxiety and imprecise symptom ascertainment; when Sibley and colleagues systematically re-examined candidate late-onset cases using multi-informant, multi-method longitudinal data, most showed either subthreshold childhood symptoms that had been missed or comorbid conditions that better explained the adult presentation. The current best reading of this literature is that genuine de novo adult-onset AD/HD is much rarer than the Moffitt-Agnew-Blais-Caye findings suggested at face value, but the findings nonetheless stand as a serious challenge to any simple conceptualisation of AD/HD as a childhood-onset neurodevelopmental disorder of which adult cases are merely residual. They also argue for caution about diagnosing adults without substantial developmental corroboration — a caution widely honoured in the breach in current clinical practice.

Persistence and outcome

How much childhood AD/HD persists? Faraone, Biederman and Mick’s (2006) meta-analysis of 21 follow-up studies gave the widely cited figure that approximately 15% of children with AD/HD still meet full criteria at age 25, and approximately 65% show partial remission with residual impairment. Barbaresi, Colligan, Weaver, Voigt, Killian and Katusic (2013), using the Rochester Epidemiology Project, reported broadly comparable persistence. Sibley et al.’s (2022) long-term follow-up of the Multimodal Treatment of ADHD (MTA) cohort challenged the stable “persister versus remitter” model, showing that the most common adult course is a fluctuating one, with individuals moving in and out of threshold diagnosis over time as environmental demands shift. This fluctuation is difficult to reconcile with a fixed neurobiological disorder and points instead toward a model in which persistent trait vulnerabilities interact with developmental context.

Outcome data nonetheless support the clinical seriousness of the syndrome at its severe end. Dalsgaard, Østergaard, Leckman, Mortensen and Pedersen (2015), in a Danish register study of 1.92 million individuals including 32,061 with AD/HD, reported a fully adjusted mortality rate ratio of 2.07 (95% CI 1.70–2.50), rising to 4.25 in those first diagnosed in adulthood, driven primarily by unnatural causes — accidents, overdose, suicide. Excess mortality remained (MRR 1.50) after excluding those with comorbid oppositional defiant disorder, conduct disorder or substance use disorder. Chang, Lichtenstein, D’Onofrio, Sjölander and Larsson (2014) showed that stimulant treatment was associated with reduced motor-vehicle crash risk in men with AD/HD. Lee, Humphreys, Flory, Liu and Glass (2011) meta-analysed the AD/HD–substance use link. Lichtenstein, Halldner, Zetterqvist, Sjölander, Serlachius, Fazel et al. (2012), in the New England Journal of Medicine, reported that stimulant medication in individuals with AD/HD was associated with reduced rates of criminal conviction. These register-based findings demonstrate that AD/HD, however constructed, predicts real-world harm.

The MTA study and the limits of long-term medication benefit

The Multimodal Treatment of ADHD (MTA) study remains the most important controlled test of AD/HD treatment. At the 14-month endpoint (MTA Cooperative Group, 1999) carefully titrated medication outperformed behavioural therapy and community care on core symptoms. At 3 years (Jensen et al., 2007), the medication advantage had attenuated. At 6–8 years (Molina, Hinshaw, Swanson, Arnold, Vitiello, Jensen et al., 2009) there was no detectable long-term advantage of any of the original treatment arms over each other on any functional outcome. The 16-year follow-up (Swanson, Arnold, Molina, Sibley, Hechtman, Hinshaw et al., 2017) reported approximately 1–2 cm of adult height suppression in those who took stimulants continuously throughout childhood and, again, no detectable academic or occupational advantage of sustained medication. The MTA is thus a study that robustly supports the short-term symptomatic efficacy of stimulants and equally robustly fails to support their long-term functional benefit. The gap between these two findings is one of the central unresolved tensions in contemporary AD/HD practice.

4. Is AD/HD a legitimate disorder?

The honest answer is: it depends on what one means by “legitimate”. The evidence for and against must be weighed carefully, neither side is frivolous, and the correct position is mixed rather than univocal.

The case for validity

Twin studies consistently yield very high heritability estimates for AD/HD. Faraone and Larsson’s (2019) review summarised the literature as giving a twin heritability of approximately 74–80%, placing AD/HD among the most heritable psychiatric conditions, on a par with schizophrenia and bipolar disorder. Familial recurrence is correspondingly elevated. However, the standard twin model’s heritability estimates are inflated by rater effects, as Kan, Dolan, Nivard, Middeldorp, van Beijsterveldt, Willemsen and Boomsma (2013) demonstrated: when the same rater assesses both twins, the “heritability” estimate rises because rater bias is counted as genetic variance. SNP-based heritability from molecular genetic studies is substantially lower, at roughly 14–22% (Demontis et al., 2023), indicating that much of the twin heritability reflects factors not captured by common genetic variation — rare variants, gene–environment interaction, non-additive effects, and measurement-model assumptions.

Genome-wide association studies have delivered the first firm molecular evidence of polygenic liability. Demontis et al. (2019), in the Psychiatric Genomics Consortium–iPSYCH meta-analysis of 20,183 cases and 35,191 controls, identified 12 genome-wide significant loci for AD/HD — the first replicable common variants. The updated Demontis et al. (2023) analysis, combining iPSYCH, deCODE and PGC data (38,691 cases, 186,843 controls), identified 27 loci and 76 candidate risk genes, enriched in genes expressed in early brain development and in midbrain dopaminergic neurons. Bivariate mixture modelling estimated that 84–98% of variants influencing AD/HD are shared with other psychiatric disorders — a finding that matters for the question of specificity discussed below. Polygenic risk scores derived from these GWAS currently explain roughly 1–4% of AD/HD variance in independent samples, which is scientifically meaningful but clinically inadequate for prediction at the individual level.

Neuroimaging findings are real but small. The ENIGMA-ADHD consortium’s mega-analysis (Hoogman et al., 2017) pooled 1,713 AD/HD cases and 1,529 controls across 23 sites and reported smaller volumes in the accumbens (Cohen’s d = −0.15), amygdala (d = −0.19), caudate (d = −0.11), hippocampus (d = −0.11), putamen (d = −0.14) and intracranial volume (d = −0.10) in AD/HD. Effect sizes were largest in children and non-significant in adults — a finding that either supports a maturational lag interpretation or, less comfortably for the diagnostic construct, suggests that the brain signature attenuates just when the adult-diagnosis surge has been concentrated. The subsequent ENIGMA cortical analyses (Hoogman et al., 2019) showed similarly small effects on surface area and thickness. Wolfers et al. (2020), applying normative modelling to ENIGMA data, demonstrated that individual AD/HD brains rarely share the same atypicality pattern — the group-level difference does not reduce to a shared neural signature. A large independent study using the Adolescent Brain Cognitive Development (ABCD) cohort of over 10,000 children (Bernanke, Sheldrick, Woodworth & Bloch, 2022) found no significant differences in subcortical volume or cortical thickness between children with and without AD/HD. These findings must be squared honestly: group-level neuroanatomical differences exist at small effect size, are inconsistent across cohorts, are absent in adults, and are useless for individual diagnosis.

Stimulant medication efficacy is among the most robustly replicated findings in psychiatric pharmacology. Cortese, Adamo, Del Giovane, Mohr-Jensen, Hayes, Carucci et al. (2018), in the Lancet Psychiatry network meta-analysis of 133 double-blind RCTs, reported short-term symptom reductions with standardised mean differences of approximately −0.78 for methylphenidate in children and adolescents and −1.02 for amphetamines, with amphetamines superior in adults (SMDs as large as −0.94 versus comparators). Acceptability data showed amphetamines less well tolerated than placebo in both age groups. The meta-analysis explicitly covered time points closest to 12, 26 and 52 weeks; the evidence base thins rapidly beyond a year.

Finally, Faraone et al.’s (2021) “World Federation of ADHD International Consensus Statement: 208 Evidence-based Conclusions about the Disorder”, endorsed by 80 authors from 27 countries and 366 signatories, was an explicit attempt to consolidate the validity case. It asserts that AD/HD is a valid disorder meeting Robins and Guze criteria; that prevalence is roughly 5.9% in youth and 2.5% in adults; that heritability is high; that untreated AD/HD carries serious adverse outcomes; and that medications are effective and generally safe. The statement is the most thorough pro-validity document in the literature.

The case for scepticism

The sceptical case is not a single argument but a cluster of convergent ones, and it is stronger than many clinicians appreciate.

Allen Frances, chair of the DSM-IV task force, has repeatedly described AD/HD as one of the “false epidemics” of recent psychiatry, driven by pharmaceutical marketing, diagnostic loosening, and the pathologising of ordinary childhood variation (Frances, 2013, Saving Normal). Sami Timimi (2002, 2017, 2021) has argued that AD/HD is a cultural construct whose rise tracks with social, educational and economic changes rather than neurobiological discovery. Peter Conrad’s (2007) Medicalization of Society and his earlier “From hyperactive children to ADHD adults: observations on the expansion of medical categories” (Conrad & Potter, 2000) document in detail how the diagnostic category has expanded across the life course in tandem with pharmaceutical markets. Joanna Moncrieff and Timimi (Timimi et al., 2004; Moncrieff & Timimi, 2010, 2011) have consistently disputed the biomedical framing, and Moncrieff, Timimi and Horowitz (2022) issued a critical response to the Faraone et al. consensus arguing that it conflates construct validity with biological reality, overstates prevalence stability, and minimises the harms of medication.

The relative age effect is perhaps the single most embarrassing finding for the construct as currently applied. Morrow, Garland, Wright, Maclure, Taylor and Dormuth (2012), in a Canadian population cohort of 937,943 children, found that children born in December (the youngest in their British Columbian school cohort) were 30% more likely to receive an AD/HD diagnosis and 41% more likely to be medicated than their January-born classmates. Elder (2010) reached similar conclusions in US data. Layton, Barnett, Hicks and Jena (2018), in the New England Journal of Medicine, analysed approximately 400,000 US children and found that in states with a 1 September school-entry cutoff, children born in August (the youngest) had a 34% higher AD/HD diagnosis rate and 32% higher stimulant treatment rate than children born in September (the oldest) — a difference that did not appear in states without that cutoff, nor for any other adjacent month pair, nor for asthma, diabetes or obesity. Sayal, Chudal, Hinkka-Yli-Salomäki, Joelsson and Sourander (2017) confirmed the effect in a systematic review; Caye et al.’s (2020) meta-analysis summarised the relative risk of an AD/HD diagnosis at 1.34 (95% CI 1.26–1.43) for children in the youngest third of their school cohort. Whitely, Raven, Efron, Kealy, Bor, Hay, Alati and Zubrick (2019) demonstrated the same pattern in Western Australian data. The implication is difficult to escape: a meaningful fraction of AD/HD diagnoses reflect relative immaturity rather than underlying pathology, and the diagnostic process is sensitive to the trivial accident of birth month.

Cross-national variation compounds the worry. Diagnostic rates in the US have exceeded 10% of children for more than a decade; France and Japan have historically diagnosed at a fraction of that rate; even within Europe, ratios of five- to tenfold are common (Hinshaw & Scheffler, 2014, The ADHD Explosion). No biomedical theory of AD/HD predicts such variation; sociological theories predict it straightforwardly.

The absence of a biological test remains a structural weakness. Despite decades of biomarker research, no laboratory, neurocognitive or imaging test is sensitive or specific enough for individual diagnosis. The Faraone et al. (2021) consensus itself acknowledges that AD/HD cannot be diagnosed by rating scales alone, by neuropsychological tests, or by brain imaging. Continuous performance tests, QEEG, and eye-tracking paradigms have been repeatedly proposed and repeatedly failed in head-to-head comparison with clinical interview. Rating scales, meanwhile, carry well-documented cultural, racial and sex biases: Morgan, Staff, Hillemeier, Farkas and Maczuga (2013) and subsequent work have shown that Black and Hispanic children in the US are systematically under-diagnosed relative to symptom profiles, while Cénat et al. (2021) reported a higher pooled AD/HD rate in Black US youth in a more recent meta-analysis — findings that reflect service-access complexities rather than a stable biological base rate.

Group-level neuroimaging effect sizes are, as noted, trivially small. The ENIGMA findings would be considered scientifically unremarkable for group comparisons in any other field and are non-diagnostic at the individual level. Publication bias in functional neuroimaging of AD/HD has been documented (Samea et al., 2019), and the broader methodological crisis in underpowered neuroimaging (Button et al., 2013) applies with full force to this literature.

Environmental and contextual explanations of AD/HD-like symptoms are substantial. Sleep deprivation in children and adolescents reliably produces inattention, impulsivity and emotional dysregulation indistinguishable in practice from AD/HD (Owens, 2008; Gruber, 2013). Digital media exposure shows a consistent small-to-moderate association with AD/HD symptom emergence in prospective data (Ra et al., 2018, JAMA). Adverse childhood experiences show a clear dose-response with AD/HD diagnosis — Brown, Brown, Briggs, German, Belamarich and Oyeku (2017) reported that children with four or more ACEs had three times the odds of an AD/HD diagnosis compared with children without ACEs. Educational system factors — start ages, pedagogical rigidity, long sedentary school days — plausibly contribute to the expression of inattention and activity problems that schools then refer for diagnosis.

The pharmaceutical industry’s role cannot be ignored in good conscience. Direct-to-consumer prescription advertising is legal only in the US and New Zealand. Shire’s and later Takeda’s adult AD/HD marketing campaigns, beginning in the mid-2000s, coincided closely with the expansion of the adult market. Alan Schwarz’s ADHD Nation (2016) documented conflicts of interest among influential researchers and the history of aggressive market cultivation. None of this proves the disorder false; it does mean that the incentive structure surrounding AD/HD diagnosis and treatment is not neutral.

Weighing the arguments

A balanced reading is that AD/HD has genuine construct validity at the severe, impairing, persistent, childhood-onset end, where heritability is high, outcomes are adverse, and treatment responses are robust. At the diffuse edges of current practice — mild adult self-referred presentations, stress-related inattention in high-performing adults, the relative-age-effect children at the young end of their school cohort, and the growing category of late-life cognitive complaint — the construct’s validity is much weaker, and a substantial fraction of diagnoses in this territory are most charitably described as descriptive labels for functional struggle rather than identifications of a discrete neurobiological condition. Neither uncritical endorsement nor polemical dismissal is warranted; the evidence supports a gradient.

5. Differential diagnosis: what else could this be?

The symptoms the DSM calls AD/HD are non-specific. Inattention, restlessness, impulsivity, disorganisation and emotional volatility are final common pathways for a large number of conditions, and the single greatest clinical failing in contemporary AD/HD assessment is premature diagnostic closure — accepting an inattention profile at face value without working through alternatives.

Trauma and complex trauma are chronically under-recognised. Children exposed to maltreatment, family violence, neglect or prolonged insecurity present with hypervigilance, difficulty concentrating, emotional reactivity and restlessness that are easily mistaken for AD/HD (Szymanski, Sapanski & Conway, 2011). Brown et al. (2017) demonstrated a dose-response between ACEs and AD/HD diagnosis. Van der Kolk’s developmental trauma disorder framework, while not adopted in DSM, captures a phenotype that overlaps substantially with AD/HD-combined presentation. The clinical implication is that any child or adult presenting with an AD/HD-compatible profile should be screened systematically for trauma history before diagnostic commitment.

Anxiety disorders produce concentration impairment (a DSM criterion for generalised anxiety disorder) and restlessness. Jarrett and Ollendick’s (2008) meta-analysis estimated AD/HD–anxiety comorbidity at roughly 25%. The differential is difficult: anxious children are often inattentive because cognitive resources are consumed by worry, not because of primary attentional deficit. Stimulants can worsen anxiety, making diagnostic accuracy clinically consequential.

Depression in both children and adults produces concentration impairment, psychomotor changes and reduced task completion. In adolescents, irritable depression is easily misread as AD/HD. Comorbidity estimates are 15–30% (Biederman, Faraone, Mick & Lelon, 1995).

Autism spectrum disorder was a DSM-IV exclusion and is now permitted to co-occur. Meta-analytic estimates of comorbidity in clinical samples run to 30–50% (Rong, Yang, Jin & Wang, 2021). Shared executive dysfunction, sensory sensitivities and social incoordination overlap substantially with AD/HD symptoms. The “AuDHD” advocacy discourse reflects genuine clinical overlap but also reflects the blurring of disorder boundaries in the identity-based neurodivergence movement. The differential hinges on the presence or absence of social-communication fundamentals, not on inattention per se.

Sleep disorders deserve a special place in the differential because they can produce the full AD/HD phenotype and resolve it with treatment. Paediatric obstructive sleep apnoea is associated with inattention and hyperactivity, and adenotonsillectomy frequently resolves these symptoms (Chervin, Archbold, Dillon, Panahi, Pituch, Dahl & Guilleminault, 2002). Delayed sleep phase disorder is elevated in adolescents and adults with AD/HD (Van Veen, Kooij, Boonstra, Gordijn & Van Someren, 2010); restless legs syndrome, narcolepsy and chronic insomnia all produce overlapping phenotypes. Cortese, Faraone, Konofal and Lecendreux (2009) meta-analysed the sleep-AD/HD literature and demonstrated the reciprocal complexity. Any adult presenting for AD/HD assessment should have sleep disorder screening as a mandatory step.

Bipolar disorder, particularly bipolar-II with hypomanic irritability, is frequently misidentified as AD/HD in adolescents and young adults; conversely, paediatric bipolar disorder was over-diagnosed in the US during the 2000s, a problem partly addressed by DSM-5’s introduction of Disruptive Mood Dysregulation Disorder. The differential turns on episodicity, sleep reduction with preserved energy, and mood quality.

Personality disorders — particularly borderline personality disorder — overlap substantially with adult AD/HD in the territory of emotional dysregulation, impulsivity and interpersonal volatility (Philipsen, 2006; Matthies & Philipsen, 2014; Moukhtarian, Mintah, Moran & Asherson, 2018). Cluster B features in general show extensive symptomatic overlap. Distinguishing chronic trait dysregulation rooted in early relational disruption from neurodevelopmental dysregulation is frequently impossible from a cross-sectional assessment alone.

Learning disorders (dyslexia, dyscalculia, developmental language disorder) produce apparent inattention through task avoidance and cognitive fatigue; Willcutt and Pennington (2000) documented the comorbidity and the diagnostic confusion it creates. Intellectual disability elevates AD/HD prevalence but complicates assessment, and giftedness can produce classroom boredom, daydreaming and task refusal that parents and teachers read as inattention (Webb et al., 2005).

Substance use produces AD/HD-compatible cognitive and behavioural changes, and AD/HD increases subsequent substance use risk (Lee et al., 2011). Stimulant misuse and cannabis use in particular complicate differential diagnosis in young adults.

Medical conditions producing AD/HD-like presentations include thyroid dysfunction, iron deficiency (Konofal, Lecendreux, Arnulf & Mouren, 2004), lead exposure, absence seizures misread as inattention, post-concussive syndrome, and foetal alcohol spectrum disorder. A basic medical workup — at minimum thyroid function, full blood count with ferritin, and a developmental and medical history — is warranted before stimulant commencement.

The p-factor problem

The sheer breadth of this differential list raises a deeper question. Caspi, Houts, Belsky, Goldman-Mellor, Harrington, Israel et al. (2014) demonstrated in Dunedin data that the structure of psychopathology is better captured by a single general factor of psychopathology — the “p factor” — than by distinct diagnoses. Caspi and Moffitt (2018) extended the implications, arguing that the evidence from genetics, imaging and psychosocial research increasingly points to shared rather than disorder-specific causes. The Demontis et al. (2023) GWAS finding that 84–98% of AD/HD-influencing variants are shared with other psychiatric disorders fits this framework exactly. If a substantial part of what we call AD/HD is shared liability to psychiatric morbidity in general, then treating AD/HD as a discrete entity risks mistaking a reflection of general psychopathology severity for a specific condition.

6. Is AD/HD a unitary construct?

Even granting that AD/HD identifies something real, it is increasingly difficult to argue that it identifies one thing.

Subtype/presentation instability is well established. Lahey, Pelham, Loney, Lee and Willcutt (2005) documented that DSM-IV subtypes are unstable over time within individuals, with children moving between hyperactive-impulsive, inattentive and combined presentations across longitudinal assessment. Willcutt’s (2012) meta-analytic review contributed to the DSM-5 decision to rename “subtypes” as “presentations”, a terminological concession to the fact that the categories do not identify stable kinds of people.

Factor structure is dominated by a two-factor solution (inattention; hyperactivity-impulsivity), with some support for bifactor models in which a general AD/HD factor coexists with specific factors (Martel, Roberts & Gremillion, 2013; Willoughby, Holochwost, Blanton & Blair, 2014). The factor structure is replicable but does not by itself speak to underlying causal homogeneity.

Sluggish Cognitive Tempo, recently re-labelled Cognitive Disengagement Syndrome (CDS; Becker, Willcutt, Leopold, Fredrick, Smith, Jacobson et al., 2023), describes a phenotype of daydreaming, mental fog, slow information processing, hypoactivity and lethargy that overlaps with AD/HD-inattentive presentation but appears to be at least partly distinct. Barkley has argued that CDS is a separate construct; Becker and colleagues are more measured, presenting it as a related but differentiable syndrome with a distinct neurocognitive signature (slower processing speed rather than executive dysfunction) and different external correlates (internalising rather than externalising comorbidity). Approximately 40% of children meeting AD/HD-inattentive criteria also meet CDS criteria, and a substantial minority of CDS cases do not meet AD/HD criteria at all, suggesting the constructs are overlapping rather than identical. CDS is not in DSM-5-TR but is gaining empirical traction.

Neurocognitive heterogeneity is pervasive. Willcutt, Doyle, Nigg, Faraone and Pennington’s (2005) meta-analysis of executive function in AD/HD produced the often-quoted finding that executive dysfunction is detectable at group level but that only 30–50% of individuals with AD/HD show deficits on any given executive task — and the specific tasks on which individuals show deficits differ. Nigg (2005) emphasised response variability as a more consistent marker than mean performance. Castellanos and Tannock (2002) proposed multiple endophenotypes. Fair, Bathula, Nikolas and Nigg (2012) used data-driven clustering to identify neurocognitive subtypes within AD/HD. Karalunas, Fair, Musser, Aykes, Iyer and Nigg (2014) identified temperament-based subtypes with distinct neural signatures.

Sonuga-Barke’s pathway models formalised the heterogeneity. The original dual-pathway model (Sonuga-Barke, 2002, 2003) distinguished an executive-dysfunction route from a delay-aversion (motivational/reward) route to the AD/HD phenotype; the later triple-pathway model (Sonuga-Barke, Bitsakou & Thompson, 2010) added temporal processing. Coghill, Seth and Matthews (2014) provided empirical support in clinical samples. The clinical implication is that two children meeting AD/HD criteria may have arrived at the behavioural phenotype via entirely different cognitive-neural routes, which has obvious consequences for treatment matching.

Neuroimaging heterogeneity follows the same pattern. Wolfers et al.’s (2020) normative modelling showed that AD/HD individuals share very little atypicality with one another — the group-level signal is driven by different subsets of individuals showing different deviations, not by a common brain profile.

Alternative nosological frameworks increasingly treat AD/HD as a convenience label rather than a natural kind. The Research Domain Criteria (RDoC) framework of the US National Institute of Mental Health (Insel et al., 2010; Cuthbert & Insel, 2013) distributes AD/HD-relevant phenomena across multiple domains: cognitive control, working memory, arousal/regulatory systems, positive valence (reward processing) and sensorimotor systems. The Hierarchical Taxonomy of Psychopathology (HiTOP; Kotov et al., 2017, 2021) locates AD/HD within a disinhibited externalising spectrum, where it shares substantial variance with oppositional defiant disorder, conduct disorder, antisocial personality disorder and substance use; inattention symptoms load more broadly, cross-cutting internalising as well. Under both frameworks, AD/HD is not a basic unit of psychopathology but a surface label for a convergence of more fundamental dimensional liabilities.

The implication for clinicians is unavoidable: saying that a patient “has AD/HD” conveys much less specific information than it appears to. The phrase identifies a behavioural profile, not a discrete condition. Two patients with the same diagnosis may share little in the way of aetiology, neurocognitive mechanism, treatment responsiveness or prognosis.

7. Critical synthesis: what to do with AD/HD

The most defensible position on AD/HD in 2026 is one that some commentators have called “valid but overdiagnosed”. The construct captures something real: a familial, heritable, neurodevelopmentally-anchored pattern of inattention, disinhibition and self-regulation difficulty that, at its severe end, is impairing across the lifespan and responsive to stimulant medication. It is not a social fiction. At the same time, the diagnostic boundary as currently implemented in clinical practice has drifted well into territory where the evidence for discrete pathology is thin, where alternative explanations are plentiful, and where the balance of benefit and harm from medication is uncertain. The relative age effect alone — robust, international, and of substantial magnitude — establishes that a meaningful fraction of current diagnoses cannot be explained by underlying pathology.

Stimulant medication has the clearest short-term symptom efficacy in psychiatric pharmacology. It also has the weakest long-term functional evidence of any widely prescribed psychotropic. The MTA data, now extending to 16 years, show robust short-term symptomatic benefit, attenuation of group differences by three years, and no detectable long-term functional advantage. Register-based studies (Chang et al., 2014; Lichtenstein et al., 2012) show reductions in accidents and criminal conviction during medicated periods, but these findings coexist with concerning signals about long-term cardiovascular risk, growth suppression, and the under-studied question of the neurodevelopmental consequences of sustained dopaminergic stimulation in the developing brain. Honest clinical practice must hold both findings at once: stimulants work, in a meaningful sense, for the people for whom they work; and the long-term balance sheet is not established.

The expansion of adult AD/HD diagnosis since 2020 warrants particular scrutiny. The pandemic-era surge in self-referred adult diagnosis, often via minimally-assessed telehealth pathways and often catalysed by social-media self-identification, is almost certainly capturing a genuinely impaired sub-population that was previously under-served, a larger sub-population whose functional difficulties reflect burnout, anxiety, sleep disruption, modern work-environment mismatch and the general cognitive toll of contemporary life, and a smaller sub-population for whom the diagnostic label and stimulant prescription provide symptomatic relief regardless of whether they meet rigorous developmental criteria. Distinguishing these groups is clinically difficult but ethically necessary.

The rise of the neurodivergence framing complicates matters further. The movement has produced real benefits: reduced stigma, stronger self-advocacy, better workplace accommodation, and a partial shift from deficit-based to difference-based language. It has also had the unintended effect of turning a diagnostic category into an identity. When AD/HD becomes something one “is” rather than something one “has”, the epistemic standards for diagnosis loosen considerably, because challenging the diagnosis comes to feel like challenging the person. Clinicians need to navigate this terrain with respect for patient experience while retaining diagnostic rigour — affirming the reality of the person’s difficulties without affirming every particular explanation for those difficulties.

Recommendations for assessment

Careful AD/HD assessment, in children and adults alike, should be:

• Multi-informant — incorporating parent, teacher, partner and/or self-report rather than relying on any single source, with explicit attention to informant disagreement as diagnostically informative rather than noise.

• Multi-method — combining clinical interview, standardised rating scales, developmental history (including school records where possible), functional assessment, and screening for differential diagnoses rather than treating a completed rating scale as a diagnostic conclusion.

• Developmentally anchored — requiring substantial corroborating evidence of childhood symptoms before diagnosing adults, and taking seriously the implications of the Moffitt, Agnew-Blais and Caye findings about apparent adult-onset cases.

• Systematically differential — screening for trauma, sleep disorder, mood and anxiety disorders, substance use, thyroid dysfunction, iron deficiency and learning difficulties before diagnostic closure.

• Functionally focused — grounding diagnosis in clear functional impairment across settings rather than on symptom count alone, noting that the DSM criteria themselves require this.

The clinician should also be honest about what is not known. We do not know which children with AD/HD diagnoses will benefit most from medication. We do not know the long-term neurodevelopmental consequences of sustained stimulant use from childhood. We do not know how much of the construct’s validity survives the erosion of specificity documented by p-factor and HiTOP research. We do not know whether the rapid rise in adult diagnosis reflects the long-overdue correction of historical under-recognition, the over-pathologising of ordinary distress, or some combination.

Conclusion: holding complexity without collapsing into certainty

AD/HD is real. It is also a moving target. A principal clinical psychologist with four decades of experience will have watched the construct expand from a narrowly defined childhood condition affecting a small minority of disruptive boys into a lifespan neurodevelopmental category applied to roughly one in nine American children and a rapidly growing fraction of adults. Some of that expansion reflects genuine scientific progress: the recognition of inattentive presentations, the acknowledgement of persistence into adulthood, the identification of the female phenotype. Some of it reflects diagnostic inflation, pharmaceutical cultivation of the adult market, educational system pressures, and the cultural fit between a behavioural diagnosis centred on distraction and a digitally saturated economy that demands impossible sustained attention.

The most defensible clinical stance is one of calibrated commitment: diagnosing and treating confidently where the evidence is strong (severe, childhood-onset, cross-situationally impairing, treatment-responsive presentations), diagnosing cautiously where the evidence is weaker (mild, adult self-identified, single-setting, primarily subjective presentations), and resisting the current cultural pressure to treat AD/HD as either a self-evident medical fact or a social construction to be deconstructed. The disorder — or, more accurately, the loose family of conditions currently gathered under its name — is neither. It is a useful clinical heuristic for a genuinely impairing and genuinely heterogeneous behavioural phenotype, whose diagnostic boundaries deserve much more scepticism, and whose affected individuals deserve much more careful assessment, than contemporary practice typically affords.

The task for the next decade is not to settle the question of whether AD/HD is “real” — that question is malformed — but to develop a more refined nosology that distinguishes the clinically severe, neurodevelopmentally-anchored phenotype from its soft-edged community penumbra; that takes the p-factor and HiTOP findings seriously rather than treating them as inconvenient; that honestly assesses the long-term balance of stimulant medication; and that rebuilds the diagnostic process around multi-informant, developmentally-grounded, differential-diagnosis-rich assessment rather than around self-report rating scales. Until that work is done, clinicians will continue to do their best with a category that is simultaneously one of the most useful and one of the most misused constructs in psychiatry.

References

Achenbach, T. M., McConaughy, S. H., & Howell, C. T. (1987). Child/adolescent behavioral and emotional problems: Implications of cross-informant correlations for situational specificity. Psychological Bulletin, 101(2), 213–232.

Agnew-Blais, J. C., Polanczyk, G. V., Danese, A., Wertz, J., Moffitt, T. E., & Arseneault, L. (2016). Evaluation of the persistence, remission, and emergence of attention-deficit/hyperactivity disorder in young adulthood. JAMA Psychiatry, 73(7), 713–720.

American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). APA.

American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). APA.

Barbaresi, W. J., Colligan, R. C., Weaver, A. L., Voigt, R. G., Killian, J. M., & Katusic, S. K. (2013). Mortality, ADHD, and psychosocial adversity in adults with childhood ADHD: A prospective study. Pediatrics, 131(4), 637–644.

Barkley, R. A. (1997). Behavioral inhibition, sustained attention, and executive functions: Constructing a unifying theory of ADHD. Psychological Bulletin, 121(1), 65–94.

Barkley, R. A., & Fischer, M. (2019). Time reproduction deficits at young adult follow-up in childhood ADHD: The role of persistence of disorder and executive functioning. Developmental Neuropsychology, 44(1), 1–15.

Becker, S. P., Willcutt, E. G., Leopold, D. R., Fredrick, J. W., Smith, Z. R., Jacobson, L. A., et al. (2023). Report of a work group on sluggish cognitive tempo: Key research directions and a consensus change in terminology to cognitive disengagement syndrome. Journal of the American Academy of Child and Adolescent Psychiatry, 62(6), 629–645.

Bernanke, J., Sheldrick, R. C., Woodworth, H., & Bloch, M. H. (2022). Structural brain measures and ADHD in the Adolescent Brain Cognitive Development (ABCD) study. Journal of Child Psychology and Psychiatry, 63(11), 1334–1344.

Biederman, J., Faraone, S. V., Mick, E., & Lelon, E. (1995). Psychiatric comorbidity among referred juveniles with major depression: Fact or artifact? Journal of the American Academy of Child and Adolescent Psychiatry, 34(5), 579–590.

Bradley, C. (1937). The behavior of children receiving benzedrine. American Journal of Psychiatry, 94(3), 577–585.

Brown, N. M., Brown, S. N., Briggs, R. D., German, M., Belamarich, P. F., & Oyeku, S. O. (2017). Associations between adverse childhood experiences and ADHD diagnosis and severity. Academic Pediatrics, 17(4), 349–355.

Button, K. S., Ioannidis, J. P. A., Mokrysz, C., Nosek, B. A., Flint, J., Robinson, E. S. J., & Munafò, M. R. (2013). Power failure: Why small sample size undermines the reliability of neuroscience. Nature Reviews Neuroscience, 14(5), 365–376.

Caspi, A., Houts, R. M., Belsky, D. W., Goldman-Mellor, S. J., Harrington, H., Israel, S., et al. (2014). The p factor: One general psychopathology factor in the structure of psychiatric disorders? Clinical Psychological Science, 2(2), 119–137.

Caspi, A., & Moffitt, T. E. (2018). All for one and one for all: Mental disorders in one dimension. American Journal of Psychiatry, 175(9), 831–844.

Castellanos, F. X., & Tannock, R. (2002). Neuroscience of attention-deficit/hyperactivity disorder: The search for endophenotypes. Nature Reviews Neuroscience, 3(8), 617–628.

Caye, A., Rocha, T. B.-M., Anselmi, L., Murray, J., Menezes, A. M. B., Barros, F. C., et al. (2016). Attention-deficit/hyperactivity disorder trajectories from childhood to young adulthood: Evidence from a birth cohort supporting a late-onset syndrome. JAMA Psychiatry, 73(7), 705–712.

Caye, A., Petresco, S., de Barros, A. J. D., Bressan, R. A., Gadelha, A., Gonçalves, H., et al. (2020). Relative age and attention-deficit/hyperactivity disorder: Data from three epidemiological cohorts and a meta-analysis. Journal of the American Academy of Child and Adolescent Psychiatry, 59(8), 990–997.

Cénat, J. M., Blais-Rochette, C., Morse, C., Vandette, M.-P., Noorishad, P.-G., Kogan, C., et al. (2021). Prevalence and risk factors associated with attention-deficit/hyperactivity disorder among US Black individuals: A systematic review and meta-analysis. JAMA Psychiatry, 78(1), 21–28.

Chang, Z., Lichtenstein, P., D’Onofrio, B. M., Sjölander, A., & Larsson, H. (2014). Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: A population-based study. JAMA Psychiatry, 71(3), 319–325.

Chervin, R. D., Archbold, K. H., Dillon, J. E., Panahi, P., Pituch, K. J., Dahl, R. E., & Guilleminault, C. (2002). Inattention, hyperactivity, and symptoms of sleep-disordered breathing. Pediatrics, 109(3), 449–456.

Coghill, D. R., Seth, S., & Matthews, K. (2014). A comprehensive assessment of memory, delay aversion, timing, inhibition, decision making and variability in attention deficit hyperactivity disorder. Psychological Medicine, 44(9), 1989–2001.

Conrad, P. (2007). The medicalization of society: On the transformation of human conditions into treatable disorders. Johns Hopkins University Press.

Conrad, P., & Potter, D. (2000). From hyperactive children to ADHD adults: Observations on the expansion of medical categories. Social Problems, 47(4), 559–582.

Cortese, S., Adamo, N., Del Giovane, C., Mohr-Jensen, C., Hayes, A. J., Carucci, S., et al. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: A systematic review and network meta-analysis. Lancet Psychiatry, 5(9), 727–738.

Cortese, S., Faraone, S. V., Konofal, E., & Lecendreux, M. (2009). Sleep in children with attention-deficit/hyperactivity disorder: Meta-analysis of subjective and objective studies. Journal of the American Academy of Child and Adolescent Psychiatry, 48(9), 894–908.

Cuthbert, B. N., & Insel, T. R. (2013). Toward the future of psychiatric diagnosis: The seven pillars of RDoC. BMC Medicine, 11, 126.

Dalsgaard, S., Østergaard, S. D., Leckman, J. F., Mortensen, P. B., & Pedersen, M. G. (2015). Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: A nationwide cohort study. The Lancet, 385(9983), 2190–2196.

de Jong, M., Wynchank, D. S. M. R., Michielsen, M., Beekman, A. T. F., & Kooij, J. J. S. (2023). A qualitative study on the climacteric experiences of women with ADHD. Journal of Attention Disorders, advance online publication.

Demontis, D., Walters, R. K., Martin, J., Mattheisen, M., Als, T. D., Agerbo, E., et al. (2019). Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nature Genetics, 51(1), 63–75.

Demontis, D., Walters, G. B., Athanasiadis, G., Walters, R., Therrien, K., Nielsen, T. T., et al. (2023). Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains. Nature Genetics, 55(2), 198–208.

Elder, T. E. (2010). The importance of relative standards in ADHD diagnoses: Evidence based on exact birth dates. Journal of Health Economics, 29(5), 641–656.

Fair, D. A., Bathula, D., Nikolas, M. A., & Nigg, J. T. (2012). Distinct neuropsychological subgroups in typically developing youth inform heterogeneity in children with ADHD. Proceedings of the National Academy of Sciences, 109(17), 6769–6774.

Faraone, S. V., Banaschewski, T., Coghill, D., Zheng, Y., Biederman, J., Bellgrove, M. A., et al. (2021). The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neuroscience and Biobehavioral Reviews, 128, 789–818.

Faraone, S. V., & Biederman, J. (2016). Can attention-deficit/hyperactivity disorder onset occur in adulthood? JAMA Psychiatry, 73(7), 655–656.

Faraone, S. V., Biederman, J., & Mick, E. (2006). The age-dependent decline of attention deficit hyperactivity disorder: A meta-analysis of follow-up studies. Psychological Medicine, 36(2), 159–165.

Faraone, S. V., & Larsson, H. (2019). Genetics of attention deficit hyperactivity disorder. Molecular Psychiatry, 24(4), 562–575.

Faraone, S. V., Rostain, A. L., Blader, J., Busch, B., Childress, A. C., Connor, D. F., & Newcorn, J. H. (2019). Practitioner Review: Emotional dysregulation in attention-deficit/hyperactivity disorder — implications for clinical recognition and intervention. Journal of Child Psychology and Psychiatry, 60(2), 133–150.

Fayyad, J., Sampson, N. A., Hwang, I., Adamowski, T., Aguilar-Gaxiola, S., Al-Hamzawi, A., et al. (2017). The descriptive epidemiology of DSM-IV adult ADHD in the World Health Organization World Mental Health Surveys. Attention Deficit and Hyperactivity Disorders, 9(1), 47–65.

Frances, A. (2013). Saving normal: An insider’s revolt against out-of-control psychiatric diagnosis, DSM-5, big pharma, and the medicalization of ordinary life. William Morrow.

Gruber, R. (2013). Making room for sleep: The relevance of sleep to psychology and the rationale for development of preventative sleep education programs for children and adolescents in the community. Canadian Psychology, 54(1), 62–71.

Hinshaw, S. P., Owens, E. B., Zalecki, C., Huggins, S. P., Montenegro-Nevado, A. J., Schrodek, E., & Swanson, E. N. (2012). Prospective follow-up of girls with attention-deficit/hyperactivity disorder into early adulthood: Continuing impairment includes elevated risk for suicide attempts and self-injury. Journal of Consulting and Clinical Psychology, 80(6), 1041–1051.

Hinshaw, S. P., & Scheffler, R. M. (2014). The ADHD explosion: Myths, medication, money, and today’s push for performance. Oxford University Press.

Hoogman, M., Bralten, J., Hibar, D. P., Mennes, M., Zwiers, M. P., Schweren, L. S. J., et al. (2017). Subcortical brain volume differences in participants with attention deficit hyperactivity disorder in children and adults: A cross-sectional mega-analysis. Lancet Psychiatry, 4(4), 310–319.

Hoogman, M., Muetzel, R., Guimaraes, J. P., Shumskaya, E., Mennes, M., Zwiers, M. P., et al. (2019). Brain imaging of the cortex in ADHD: A coordinated analysis of large-scale clinical and population-based samples. American Journal of Psychiatry, 176(7), 531–542.

Insel, T., Cuthbert, B., Garvey, M., Heinssen, R., Pine, D. S., Quinn, K., et al. (2010). Research domain criteria (RDoC): Toward a new classification framework for research on mental disorders. American Journal of Psychiatry, 167(7), 748–751.

Jarrett, M. A., & Ollendick, T. H. (2008). A conceptual review of the comorbidity of attention-deficit/hyperactivity disorder and anxiety: Implications for future research and practice. Clinical Psychology Review, 28(7), 1266–1280.

Jensen, P. S., Arnold, L. E., Swanson, J. M., Vitiello, B., Abikoff, H. B., Greenhill, L. L., et al. (2007). 3-year follow-up of the NIMH MTA study. Journal of the American Academy of Child and Adolescent Psychiatry, 46(8), 989–1002.

Kan, K.-J., Dolan, C. V., Nivard, M. G., Middeldorp, C. M., van Beijsterveldt, C. E. M., Willemsen, G., & Boomsma, D. I. (2013). Genetic and environmental stability in attention problems across the lifespan: Evidence from the Netherlands Twin Register. Journal of the American Academy of Child and Adolescent Psychiatry, 52(1), 12–25.

Karalunas, S. L., Fair, D., Musser, E. D., Aykes, K., Iyer, S. P., & Nigg, J. T. (2014). Subtyping attention-deficit/hyperactivity disorder using temperament dimensions: Toward biologically based nosologic criteria. JAMA Psychiatry, 71(9), 1015–1024.

Konofal, E., Lecendreux, M., Arnulf, I., & Mouren, M.-C. (2004). Iron deficiency in children with attention-deficit/hyperactivity disorder. Archives of Pediatrics and Adolescent Medicine, 158(12), 1113–1115.

Kotov, R., Krueger, R. F., Watson, D., Achenbach, T. M., Althoff, R. R., Bagby, R. M., et al. (2017). The Hierarchical Taxonomy of Psychopathology (HiTOP): A dimensional alternative to traditional nosologies. Journal of Abnormal Psychology, 126(4), 454–477.

Kotov, R., Krueger, R. F., Watson, D., Cicero, D. C., Conway, C. C., DeYoung, C. G., et al. (2021). The Hierarchical Taxonomy of Psychopathology (HiTOP): A quantitative nosology based on consensus of evidence. Annual Review of Clinical Psychology, 17, 83–108.

Lahey, B. B., Pelham, W. E., Loney, J., Lee, S. S., & Willcutt, E. (2005). Instability of the DSM-IV subtypes of ADHD from preschool through elementary school. Archives of General Psychiatry, 62(8), 896–902.

Layton, T. J., Barnett, M. L., Hicks, T. R., & Jena, A. B. (2018). Attention deficit–hyperactivity disorder and month of school enrollment. New England Journal of Medicine, 379(22), 2122–2130.

Lee, S. S., Humphreys, K. L., Flory, K., Liu, R., & Glass, K. (2011). Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: A meta-analytic review. Clinical Psychology Review, 31(3), 328–341.

Lichtenstein, P., Halldner, L., Zetterqvist, J., Sjölander, A., Serlachius, E., Fazel, S., et al. (2012). Medication for attention deficit–hyperactivity disorder and criminality. New England Journal of Medicine, 367(21), 2006–2014.

Martel, M. M., Roberts, B., & Gremillion, M. L. (2013). Emerging control and disruptive behavior disorders during early childhood. Developmental Neuropsychology, 38(3), 153–166.

Matthies, S. D., & Philipsen, A. (2014). Common ground in attention deficit hyperactivity disorder (ADHD) and borderline personality disorder (BPD)—review of recent findings. Borderline Personality Disorder and Emotion Dysregulation, 1, 3.

Moffitt, T. E., Houts, R., Asherson, P., Belsky, D. W., Corcoran, D. L., Hammerle, M., et al. (2015). Is adult ADHD a childhood-onset neurodevelopmental disorder? Evidence from a four-decade longitudinal cohort study. American Journal of Psychiatry, 172(10), 967–977.

Molina, B. S. G., Hinshaw, S. P., Swanson, J. M., Arnold, L. E., Vitiello, B., Jensen, P. S., et al. (2009). The MTA at 8 years: Prospective follow-up of children treated for combined-type ADHD in a multisite study. Journal of the American Academy of Child and Adolescent Psychiatry, 48(5), 484–500.

Moncrieff, J., & Timimi, S. (2010). Is ADHD a valid diagnosis in adults? No. BMJ, 340, c547.

Moncrieff, J., & Timimi, S. (2011). Critical analysis of the concept of adult attention-deficit hyperactivity disorder. The Psychiatrist, 35(9), 334–338.

Moncrieff, J., Timimi, S., & Horowitz, M. (2022). Critical response to “The World Federation of ADHD International Consensus Statement”. [Commentary in peer-reviewed exchange].

Morgan, P. L., Staff, J., Hillemeier, M. M., Farkas, G., & Maczuga, S. (2013). Racial and ethnic disparities in ADHD diagnosis from kindergarten to eighth grade. Pediatrics, 132(1), 85–93.

Morrow, R. L., Garland, E. J., Wright, J. M., Maclure, M., Taylor, S., & Dormuth, C. R. (2012). Influence of relative age on diagnosis and treatment of attention-deficit/hyperactivity disorder in children. Canadian Medical Association Journal, 184(7), 755–762.

Moukhtarian, T. R., Mintah, R. S., Moran, P., & Asherson, P. (2018). Emotional dysregulation in attention-deficit/hyperactivity disorder and borderline personality disorder. Borderline Personality Disorder and Emotion Dysregulation, 5, 9.

MTA Cooperative Group. (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 56(12), 1073–1086.

Nigg, J. T. (2005). Neuropsychologic theory and findings in attention-deficit/hyperactivity disorder: The state of the field and salient challenges for the coming decade. Biological Psychiatry, 57(11), 1424–1435.

Owens, J. A. (2008). Sleep disorders and attention-deficit/hyperactivity disorder. Current Psychiatry Reports, 10(5), 439–444.

Philipsen, A. (2006). Differential diagnosis and comorbidity of attention-deficit/hyperactivity disorder (ADHD) and borderline personality disorder (BPD) in adults. European Archives of Psychiatry and Clinical Neuroscience, 256(Suppl 1), i42–i46.

Polanczyk, G., de Lima, M. S., Horta, B. L., Biederman, J., & Rohde, L. A. (2007). The worldwide prevalence of ADHD: A systematic review and metaregression analysis. American Journal of Psychiatry, 164(6), 942–948.

Polanczyk, G. V., Willcutt, E. G., Salum, G. A., Kieling, C., & Rohde, L. A. (2014). ADHD prevalence estimates across three decades: An updated systematic review and meta-regression analysis. International Journal of Epidemiology, 43(2), 434–442.

Ra, C. K., Cho, J., Stone, M. D., De La Cerda, J., Goldenson, N. I., Moroney, E., et al. (2018). Association of digital media use with subsequent symptoms of attention-deficit/hyperactivity disorder among adolescents. JAMA, 320(3), 255–263.

Ramtekkar, U. P., Reiersen, A. M., Todorov, A. A., & Todd, R. D. (2010). Sex and age differences in attention-deficit/hyperactivity disorder symptoms and diagnoses: Implications for DSM-V and ICD-11. Journal of the American Academy of Child and Adolescent Psychiatry, 49(3), 217–228.

Roberts, B., Eisenlohr-Moul, T., & Martel, M. M. (2018). Reproductive steroids and ADHD symptoms across the menstrual cycle. Psychoneuroendocrinology, 88, 105–114.

Rong, Y., Yang, C.-J., Jin, Y., & Wang, Y. (2021). Prevalence of attention-deficit/hyperactivity disorder in individuals with autism spectrum disorder: A meta-analysis. Research in Autism Spectrum Disorders, 83, 101759.

Samea, F., Soluki, S., Nejati, V., Zarei, M., Cortese, S., Eickhoff, S. B., et al. (2019). Brain alterations in children/adolescents with ADHD revisited: A neuroimaging meta-analysis of 96 structural and functional studies. Neuroscience and Biobehavioral Reviews, 100, 1–8.

Sayal, K., Prasad, V., Daley, D., Ford, T., & Coghill, D. (2018). ADHD in children and young people: Prevalence, care pathways, and service provision. Lancet Psychiatry, 5(2), 175–186.

Schwarz, A. (2016). ADHD nation: Children, doctors, big pharma, and the making of an American epidemic. Scribner.

Shaw, P., Stringaris, A., Nigg, J., & Leibenluft, E. (2014). Emotion dysregulation in attention deficit hyperactivity disorder. American Journal of Psychiatry, 171(3), 276–293.

Sibley, M. H., Pelham, W. E., Molina, B. S. G., Gnagy, E. M., Waxmonsky, J. G., Waschbusch, D. A., et al. (2012). When diagnosing ADHD in young adults emphasize informant reports, DSM items, and impairment. Journal of Consulting and Clinical Psychology, 80(6), 1052–1061.

Sibley, M. H., Rohde, L. A., Swanson, J. M., Hechtman, L. T., Molina, B. S. G., Mitchell, J. T., et al. (2018). Late-onset ADHD reconsidered with comprehensive repeated assessments between ages 10 and 25. American Journal of Psychiatry, 175(2), 140–149.

Sibley, M. H., Arnold, L. E., Swanson, J. M., Hechtman, L. T., Kennedy, T. M., Owens, E., et al. (2022). Variable patterns of remission from ADHD in the Multimodal Treatment Study of ADHD. American Journal of Psychiatry, 179(2), 142–151.

Simon, V., Czobor, P., Bálint, S., Mészáros, Á., & Bitter, I. (2009). Prevalence and correlates of adult attention-deficit hyperactivity disorder: Meta-analysis. British Journal of Psychiatry, 194(3), 204–211.

Song, P., Zha, M., Yang, Q., Zhang, Y., Li, X., & Rudan, I. (2021). The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis. Journal of Global Health, 11, 04009.

Sonuga-Barke, E. J. S. (2002). Psychological heterogeneity in AD/HD—A dual pathway model of behaviour and cognition. Behavioural Brain Research, 130(1–2), 29–36.

Sonuga-Barke, E. J. S. (2003). The dual pathway model of AD/HD: An elaboration of neuro-developmental characteristics. Neuroscience and Biobehavioral Reviews, 27(7), 593–604.

Sonuga-Barke, E. J. S., Bitsakou, P., & Thompson, M. (2010). Beyond the dual pathway model: Evidence for the dissociation of timing, inhibitory, and delay-related impairments in attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 49(4), 345–355.

Still, G. F. (1902). Some abnormal psychical conditions in children. The Lancet, 159, 1008–1012, 1077–1082, 1163–1168.

Swanson, J. M., Arnold, L. E., Molina, B. S. G., Sibley, M. H., Hechtman, L. T., Hinshaw, S. P., et al. (2017). Young adult outcomes in the follow-up of the Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder: Symptom persistence, source discrepancy, and height suppression. Journal of Child Psychology and Psychiatry, 58(6), 663–678.

Szymanski, K., Sapanski, L., & Conway, F. (2011). Trauma and ADHD — association or diagnostic confusion? A clinical perspective. Journal of Infant, Child, and Adolescent Psychotherapy, 10(1), 51–59.

Thomas, R., Sanders, S., Doust, J., Beller, E., & Glasziou, P. (2015). Prevalence of attention-deficit/hyperactivity disorder: A systematic review and meta-analysis. Pediatrics, 135(4), e994–e1001.

Timimi, S. (2002). Pathological child psychiatry and the medicalization of childhood. Brunner-Routledge.

Timimi, S. (2017). Non-diagnostic based approaches to helping children who could be labelled ADHD and their families. International Journal of Qualitative Studies on Health and Well-being, 12(sup1), 1298270.

Timimi, S., Moncrieff, J., Jureidini, J., Leo, J., Cohen, D., Whitfield, C., et al. (2004). A critique of the international consensus statement on ADHD. Clinical Child and Family Psychology Review, 7(1), 59–63.

Van Veen, M. M., Kooij, J. J. S., Boonstra, A. M., Gordijn, M. C. M., & Van Someren, E. J. W. (2010). Delayed circadian rhythm in adults with attention-deficit/hyperactivity disorder and chronic sleep-onset insomnia. Biological Psychiatry, 67(11), 1091–1096.

Webb, J. T., Amend, E. R., Webb, N. E., Goerss, J., Beljan, P., & Olenchak, F. R. (2005). Misdiagnosis and dual diagnoses of gifted children and adults: ADHD, bipolar, OCD, Asperger’s, depression, and other disorders. Great Potential Press.

Whitely, M., Raven, M., Efron, D., Kealy, M., Bor, W., Hay, D., Alati, R., & Zubrick, S. (2019). Attention deficit hyperactivity disorder late birthdate effect common in both high and low prescribing international jurisdictions: A systematic review. Journal of Child Psychology and Psychiatry, 60(4), 380–391.

Willcutt, E. G. (2012). The prevalence of DSM-IV attention-deficit/hyperactivity disorder: A meta-analytic review. Neurotherapeutics, 9(3), 490–499.

Willcutt, E. G., Doyle, A. E., Nigg, J. T., Faraone, S. V., & Pennington, B. F. (2005). Validity of the executive function theory of attention-deficit/hyperactivity disorder: A meta-analytic review. Biological Psychiatry, 57(11), 1336–1346.

Willcutt, E. G., & Pennington, B. F. (2000). Comorbidity of reading disability and attention-deficit/hyperactivity disorder: Differences by gender and subtype. Journal of Learning Disabilities, 33(2), 179–191.

Wolfers, T., Beckmann, C. F., Hoogman, M., Buitelaar, J. K., Franke, B., & Marquand, A. F. (2020). Individual differences v. the average patient: Mapping the heterogeneity in ADHD using normative models. Psychological Medicine, 50(2), 314–323.

World Health Organization. (2022). International statistical classification of diseases and related health problems (11th rev.). WHO.

Young, S., Adamo, N., Ásgeirsdóttir, B. B., Branney, P., Beckett, M., Colley, W., et al. (2020). Females with ADHD: An expert consensus statement taking a lifespan approach providing guidance for the identification and treatment of ADHD in girls and women.BMC Psychiatry, 20, 404.